Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

Vaccine

Volumn 27, Issue 37, 2009, Pages 5091-5095

  Brady, Rebecca C ^a   Treanor, John J ^b   Atmar, Robert L ^c   Keitel, Wendy A ^c   Edelman, Robert ^d   Chen, Wilbur H ^d   Winokur, Patricia ^e   Belshe, Robert ^f   Graham, Irene L ^f   Noah, Diana Lee ^g   Guo, Kuo ^h   Hill, Heather ^h  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SOUTHERN RESEARCH INSTITUTE   (United States)

^h EMMES CORPORATION   (United States)

Author keywords

Aluminum hydroxide; Avian influenza vaccine; Elderly

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; UNCLASSIFIED DRUG;

AGED; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INFLUENZA; INFLUENZA VIRUS A H5N1; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; MALAISE; MALE; MULTICENTER STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; AGED; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NEUTRALIZATION TESTS; VACCINATION;

EID: 67650725154     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.057     Document Type: Article

References (16)

1. World Health Organization (WHO). WHO strategic action plan for pandemic influenza. Available at: http://www.who.int/csr/resources/publications/influenza/StregPlanEPR_GIP_2006_2.pdf; 2009 [Accessed April 25].
2. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
3. United States Food and Drug Administration. FDA approves first U.S. vaccine for humans against the avian influenza virus H5N1. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01611.html; 2009 [Accessed April 25].
4. Beyer W.E., Palache A.M., Baljet M., and Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 7 5 (1989) 385-394
5. Hehme N., Engelmann H., Künzel W., Neumeier E., and Sänger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191 3-4 (2002) 203-208
6. Hehme N., Engelmann H., Kuenzel W., Neumeier E., and Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103 1-2 (2004) 163-171
7. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
8. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 198 9 (2008) 1309-1316
9. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 5 (2008) 667-675
10. Treanor J., Bernstein D., Edwards K., Zangwill K., and Noah D. Evaluation of inactivated monovalent rgA/Vietnam/1203/04 X PR8 subvirion vaccine in healthy elderly adults (abstract P731). Program and abstracts of the Options for the Control of Influenza VI Conference. 17-23 June 2007; Toronto, Canada (2007)
11. + memory B cells. PloS ONE 3 12 (2008) e3942
12. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., and Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197 4 (2008) 580-583
13. Goji N.A., Nolan C., Hill H., Wolff M., Noah D.L., Williams T.B., et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietman/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 198 5 (2008) 635-641
14. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43 9 (2006) 1135-1142
15. Podda A., and Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2 2 (2003) 197-203
16. United States Census Bureau. U.S. interim projections by age, sex, race, and Hispanic origin. March 18, 2004. Available at: http://www.census.gov/ipc/www/usinterimproj; 2009 [Accessed April 25].